Neuroendocrine differentiation and prognosis in breast adenocarcinoma

Miremadi, A; Pinder, Sarah; Lee, A H S; Bell, Jane M.; Paish, Emma C.; Wencyk, P.M.; Elston, C. W.; Nicholson, Robert Ian; Blamey, R.W.; Robertson, J. F. R.; Ellis, Ian O.

doi:10.1046/j.1365-2559.2002.01336.x

Cited by 143 publications

(125 citation statements)

References 33 publications

Supporting

Mentioning

112

Contrasting

Unclassified

Order By: Relevance

“…The importance of this definition is highlighted by 2 studies that showed that focal NE differentiation had no prognostic significance as compared with breast carcinoma NOS. 8,21 Because NEC is an uncommon and newly defined entity, to date there have been only 5 series reported 9,11-14 using this diagnostic criteria. None of those series was case controlled, all had relatively small numbers of patients, and they reached conflicting conclusions about the significance of NEC.…”

Section: Discussionmentioning

confidence: 99%

Invasive neuroendocrine carcinoma of the breast

Wei

Tian

Xing

et al. 2010

Cancer

164

View full text Add to dashboard Cite

BACKGROUND: Neuroendocrine carcinoma (NEC) of the breast, a pathologic entity newly defined in the 2003 World Health Organization classification of tumors, is a rare type of tumor that is not well recognized or studied. The purpose of this first case-controlled study is to reveal the clinicopathologic features, therapeutic response, and outcomes of patients with NEC of the breast. METHODS: Seventy-four patients with NEC of the breast who were treated at The University of Texas M. D. Anderson Cancer Center were analyzed; 68 of them had complete clinical follow-up. Two cohorts of invasive mammary carcinoma cases were selected to pair with NEC to reveal demographic, pathologic, and clinical features at presentation, along with therapeutic response to treatment and patient outcomes. RESULTS: NEC was more likely to be estrogen receptor/progesterone receptor positive and human epidermal growth factor receptor 2 negative. Despite similar age and disease stages at presentation, NEC showed a more aggressive course than invasive ductal carcinoma, with a higher propensity for local and distant recurrence and poorer overall survival. High nuclear grade, large tumor size, and regional lymph node metastasis were significant negative prognostic factors for distant recurrence-free survival; high nuclear grade and regional lymph node metastasis were also significant negative prognostic factors for overall survival. Although endocrine therapy and radiation therapy showed a trend toward improved survival, the small number of cases in this study limited the statistical power to reveal therapeutic benefits in NEC of the breast. CONCLUSIONS: NEC is a distinct type of aggressive mammary carcinoma. Novel therapeutic approaches should be explored for this uniquely different clinical entity.

show abstract

Section: Discussionmentioning

confidence: 99%

Invasive neuroendocrine carcinoma of the breast

Wei

Tian

Xing

et al. 2010

Cancer

164

View full text Add to dashboard Cite

show abstract

“…Tumors, all with neoplastic cellularity greater than 50%, were obtained with appropriate ethical approval and are detailed in Supplementary Tables 2 and 3. The breast tumors were primary operable invasive breast cancers from the Nottingham City Hospital Tumor Bank (Elston and Ellis, 1991;Parker et al, 2001;Miremadi et al, 2002). Ovarian tumors were from Addenbrooke's Hospital, Cambridge.…”

Section: Primary Tumors and Cell Linesmentioning

confidence: 99%

A 1 Mb minimal amplicon at 8p11–12 in breast cancer identifies new candidate oncogenes

et al. 2005

View full text Add to dashboard Cite

Amplification of 8p11-12 is a well-known alteration in human breast cancers but the driving oncogene has not been identified. We have developed a high-resolution comparative genomic hybridization array covering 8p11-12 and analysed 33 primary breast tumors, 20 primary ovarian tumors and 27 breast cancer cell lines. Expression analysis of the genes in the region was carried out by using real-time quantitative PCR and/or oligo-microarray profiling. In all, 24% (8/33) of the breast tumors, 5% (1/20) of the ovary tumors and 15% (4/27) of the cell lines showed 8p11-12 amplification. We identified a 1 Mb segment of common amplification that excludes previously proposed candidate genes. Some of the amplified genes did not show overexpression, whereas for others, overexpression was not specifically attributable to amplification. The genes FLJ14299, C8orf2, BRF2 and RAB11FIP, map within the 8p11-12 minimal amplicon, two have a putative function consistent with an oncogenic role, these four genes showed a strong correlation between amplification and overexpression and are therefore the best candidate driver oncogenes at 8p12.

show abstract

“…Em recente estudo, Weigelt et al demonstraram que o carcinoma celular mucinoso, variante do TNPM, possui características moleculares distintas do carcinoma ductal (23) . O carcinoma de pequenas células, outra variante do TNPM, demonstra prognóstico muito pior que outras histologias (12,15,16,24) . O NE-DCIS foi descrito pela primeira vez em 1985 (3) .…”

Section: Discussionunclassified

“…Os subtipos histológicos identificados foram sólido, de pequenas células, de grandes células, celular mucinoso, carcinoide atípico e carcinoma ductal neuroendócrino in situ (NE-DCIS) (20) . Alguns carcinomas de mama expressam áreas de diferenciação neuroendócrina, < 50% das células, porém sem impacto no prognóstico (12,21) .…”

Section: Introductionunclassified